DEFB103A and cervical cancer: In the present study, we first rigorously validated a polyclonal antibody using HPV-16 positive CaSki cervical cancer cells and then demonstrated that high-risk HPV E6 was co-localized with hBD3 in HPV-positive head and neck cancer tissues.